201
Views
11
CrossRef citations to date
0
Altmetric
Research Article

High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma

, , , , &
Pages 1306-1310 | Received 20 Nov 2011, Accepted 29 Dec 2011, Published online: 21 Feb 2012

References

  • Morton LM, Wang SS, Devesa SS, Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265–276.
  • Trneny M, Vasova I, Pytlik R, . The non-Hodgkin's lymphoma subtypes distribution and survival in Czech Republic. Klin Onkol 2007;20:341–348.
  • Swenson WT, Wooldridge JE, Lynch CF, . Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019–5026.
  • Solal-Celigny P, Roy P, Colombat P, . Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
  • van de Schans SA, Steyerberg EW, Nijziel MR, . Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. Ann Oncol 2009;20:1697–1702.
  • Buske C, Hoster E, Dreyling M, . The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006;108: 1504–1508.
  • Montoto S, Lopez-Guillermo A, Altes A, . Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004;15:1484–1489.
  • Federico M, Bellei M, Marcheselli L, . Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555–4562.
  • Prochazka V, Papajik T, Jarosova M, . Prognostic factors in follicular lymphoma in the rituximab era: how to identify a high-risk patient? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011;155:99–108.
  • Gronowitz JS, Kallander CF. Optimized assay for thymidine kinase and its application to the detection of antibodies against herpes simplex virus type 1- and 2-induced thymidine kinase. Infect Immun 1980;29:425–434.
  • Hagberg H, Gronowitz S, Killander A, . Serum thymidine kinase in acute leukaemia. Br J Cancer 1984;49:537–540.
  • Gronowitz JS, Kallander FR, Diderholm H, . Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 1984;33:5–12.
  • Li Z, Wang Y, He J, . Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas. Eur J Cancer Prev 2010;19:313–318.
  • Nisman B, Allweis T, Kaduri L, . Serum thymidine kinase 1 activity in breast cancer. Cancer Biomark 2010;7:65–72.
  • Huang S, Lin J, Guo N, . Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression. Asian Pac J Cancer Prev 2011;12:497–505.
  • Aufderklamm S, Todenhoefer T, Gakis G, . Thymidine kinase and cancer monitoring. Cancer Lett 2012;316:6–10.
  • Suzuki K, Terui Y, Nakano K, . High thymidine kinase activity is a strong predictive factor for poor prognosis in PTCLs treated by CHOP. Leuk Lymphoma 2011 Oct 13. [Epub ahead of print]
  • Pan ZL, Ji XY, Shi YM, . Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients. J Cancer Res Clin Oncol 2010;136: 1193–1199.
  • Konoplev SN, Fritsche HA, O’Brien S, . High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. Am J Clin Pathol 2010;134:472–477.
  • Ohrvik A, Lindh M, Einarsson R, . Sensitive nonradiometric method for determining thymidine kinase 1 activity. Clin Chem 2004;50:1597–1606.
  • Swerdlow SH, Campo E, Harris NL, WHO classification of tumours of haematopoietic and lymphoid tissues, Vol. 2. Lyon: IARC Press; 2008.
  • Decaudin D, Lepage E, Brousse N, . Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients—a study of the groupe d’Etude des lymphomes de l’Adulte. J Clin Oncol 1999;17:2499–2505.
  • Fisher RI, Gaynor ER, Dahlberg S, . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002–1006.
  • Federico M, Clo V, Brugiatelli M, . Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Haematologica 1998;83:800–811.
  • Prochazka V, Faber E, Raida , . Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009;153:63–66.
  • Colombat P, Biron P, Laporte JP, . BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas. Eur J Cancer 1990;26:858.
  • Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.